牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-09-11 AccNo: 0001213900-19-017773 Size: 12 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-09-10 AccNo: 0001213900-19-017547 Size: 29 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-09-06 AccNo: 0001213900-19-017365 Size: 6 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-08-30 AccNo: 0001213900-19-017031 Size: 1 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-08-29 AccNo: 0001213900-19-016894 Size: 81 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-08-08 AccNo: 0001178913-19-002121 Size: 104 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-08-05 AccNo: 0001213900-19-014615 Size: 12 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-08-06 AccNo: 0001213900-19-014657 Size: 35 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-08-01 AccNo: 0001213900-19-014313 Size: 35 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-07-31 AccNo: 0001213900-19-014201 Size: 16 KB 网页链接